Biomarkers to predict the response to cardiac resynchronization therapy

Europace. 2019 Nov 1;21(11):1609-1620. doi: 10.1093/europace/euz168.

Abstract

Cardiac resynchronization therapy (CRT) is an established non-pharmacological treatment for selected heart failure patients with wide QRS duration. However, there is a persistent number of non-responders throughout. The prediction of the CRT response is paramount to adequately select the correct patients for CRT. One of the expanding fields of research is the development of biomarkers that predict the response to CRT. A review of the available literature on biomarkers in CRT patients has been performed to formulate a critical appraisal of the available data. The main conclusion of our review is that biomarker research in this patient population is very fragmented and broad. This results in the use of non-uniform endpoints to define the CRT response, which precludes an in-depth comparison of the available data. To improve research development in this field, a uniform definition of the CRT response and relevant endpoints is necessary to better predict the CRT response.

Keywords: Biomarkers; CRT non-responder; CRT response; Cardiac resynchronization therapy; Cardiac reverse remodelling; Heart failure.

Publication types

  • Review

MeSH terms

  • Biomarkers / blood
  • Cardiac Resynchronization Therapy / methods*
  • Electrocardiography*
  • Heart Failure / blood
  • Heart Failure / physiopathology
  • Heart Failure / therapy*
  • Humans
  • Nerve Growth Factors / blood*
  • Prognosis
  • Ventricular Function, Left / physiology*
  • Ventricular Remodeling / physiology*

Substances

  • Biomarkers
  • Nerve Growth Factors
  • neurite-inducing factor